Luteolin inhibits myelin basic protein‐induced human mast cell activation and mast cell‐dependent stimulation of Jurkat T cells

Abstract

Background and purpose: Allergic inflammation and autoimmune diseases, such as atopic dermatitis, psoriasis and multiple sclerosis (MS), involve both mast cell and T‐cell activation. However, possible interactions between the two and the mechanism of such activations are largely unknown. Experimental approach: Human umbilical cord blood‐derived cultured mast cells (hCBMCs) and Jurkat T cells were incubated separately or together, following activation with myelin basic protein (MBP), as well as with or without pretreatment with the flavonoid luteolin for 15 min. The supernatant fluid was assayed for inflammatory mediators released from mast cells and interleukin (IL)‐2 release from Jurkat cells. Key results: MBP (10 μM) stimulates hCBMCs to release IL‐6, IL‐8, transforming growth factor (TGF)‐β1, tumour necrosis factor‐α (TNF‐α), vascular endothelial growth factor (VEGF), histamine and tryptase (n=6, P<0.05). Addition of mast cells to Jurkat cells activated by anti‐CD3/anti‐CD28 increases IL‐2 release by 30‐fold (n=3, P<0.05). MBP‐stimulated mast cells and their supernatant fluid further increase Jurkat cell IL‐2 release (n=3, P<0.05). Separation of mast cells and activated Jurkat cells by a Transwell permeable membrane inhibits Jurkat cell stimulation by 60%. Pretreatment of Jurkat cells with a TNF‐neutralizing antibody reduces IL‐2 release by another 40%. Luteolin pretreatment inhibits mast cell activation (n=3–6, P<0.05), Jurkat cell activation and mast cell‐dependent Jurkat cell stimulation (n=3, P<0.05). Conclusions and implications: Mast cells can stimulate activated Jurkat cells. This interaction is inhibited by luteolin, suggesting that this flavonoid may be useful in the treatment of autoimmune diseases. British Journal of Pharmacology (2008) 155, 1076–1084; doi:; published online 22 September 2008

Targeting IL-33 in Autoimmunity and Inflammation

“…MCs are the only cell type in which preformed TNF is stored in secretory granules (Olszewski et al, 2007) and released bound to heparin particles that can reach draining lymph nodes and contribute to inflammation (Kunder et al, 2009). TNF can also activate T cells Kempuraj et al, 2008). MC-derived IL-6 and transforming growth factor-b are critical for the development of Th-17 cells Suurmond et al, 2011), and MCs secrete IL-17 themselves (Kenna and Brown, 2013).…”

Partial Protection againstHelicobacter pyloriin the Absence of Mast Cells in Mice

“…TNF-␣ has been described as an immunoprotective factor produced by mast cells to efficiently recruit neutrophils to bacterium-infected tissues (15,20,22,27,35). Previous studies with other bacterial infection models showed that no cells expressing TNF-␣ mRNA were identified in mast cell-deficient Sl /Kitl Sl-d mast cell-deficient mice might offer another explanation for the reduced recruitment of neutrophils in the lamina propria.…”

Perinatal Immune Activation and Risk of Autism

“…Quercetin inhibits mast cells (Kandere-Grzybowska et al, 2006), and also inhibited and reversed acute stress-induced autistic-like behavior and the associated reduced brain glutathione levels in mice (Kumar & Goyal, 2008). Luteolin can also block mast cell activation and superstimulation of activated T-cells (Kempuraj et al, 2008;Theoharides et al, 2007a). Luteolin and its structural analog diosmin prevented MIA-induced behavioral deficits in the mouse offspring by blocking the IL-6-induced JAK2/STAT3 (Janus tyrosine kinase-2/signal transducer and activator of transcription-3) signaling pathway, both in vivo and in vitro (Parker-Athill et al, 2009).…”